Solu Therapeutics Closes $41M Series A…
BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Read More
Investor Login
Toggle navigation
Home
About
About Us
News & Events
For Entrepreneurs
Contact Us
Team
Portfolio
Ventures
Specialized Fund Management
About
Chiesi Ventures Fund
Asia Innovation Ventures
AgTech Initiatives
Specialized Holdings
Translational Medicine
About
Wake Forest Technology Development Program
Home
About
Team
Portfolio
News & Events
Contact
Ventures
Specialized Funds
Translational Medicine
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.
Investor Login
Investor Login
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.
